Regeneron Pharmaceuticals, Inc. (REGN) Key Statistics & Financial Ratios

Regeneron Pharmaceuticals, Inc. (REGN) — Price $726.47 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Regeneron Pharmaceuticals, Inc. (REGN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.

Stock Data

Price$726.47
Market Cap$74.8B
Enterprise Value$74.37B
Beta0.40
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio17.35
Price / Book2.37
P/S4.82
EV/EBITDA12.93
EV/Sales4.79
EV/FCF21.12
P/FCF21.25
Earnings Yield5.76%
FCF Yield4.71%
Dividend Yield0.50%

Profitability

Gross Margin84.86%
EBIT Margin33.61%
EBITDA Margin37.01%
Operating Margin25.56%
Net Margin27.86%
Return on Equity13.81%
Return on Assets10.37%
Return on Invested Capital9.19%
Return on Capital Employed10.97%

Financial Health

Current Ratio3.34
Quick Ratio2.78
Cash Ratio0.44
Debt / Equity0.06
Debt / Assets4.76%
Net Debt / EBITDA-0.08
Interest Coverage71.66
Piotroski F-Score5
Altman Z-Score7.49

Per-Share Data

Revenue per share150.24
Book Value per share306.68
Cash per share77.32
FCF per share34.06
Tangible Book Value per share294.02
Dividend per share3.70

Analyst Consensus

Strong Buy0
Buy34
Hold15
Sell0
Strong Sell0
Total analysts49
Avg rating (1-5)0.69

Related companies: ALNY · ARGX · CI · COR · ELV · GMAB · IDXX

Explore sector: Healthcare · Biotechnology

More sections of REGN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks